2024-04-01 2025-03-31 false No description of principal activity Capium Accounts Production 1.1 12763585 2024-04-01 2025-03-31 12763585 bus:AbridgedAccounts 2024-04-01 2025-03-31 12763585 bus:FRS102 2024-04-01 2025-03-31 12763585 bus:AuditExemptWithAccountantsReport 2024-04-01 2025-03-31 12763585 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 12763585 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 12763585 2024-04-01 2025-03-31 12763585 2025-03-31 12763585 bus:RegisteredOffice 2024-04-01 2025-03-31 12763585 core:WithinOneYear 2025-03-31 12763585 core:AfterOneYear 2025-03-31 12763585 1 2024-04-01 2025-03-31 12763585 bus:Director1 2024-04-01 2025-03-31 12763585 bus:Director1 2025-03-31 12763585 bus:Director1 2023-08-01 2024-03-31 12763585 bus:Director2 2024-04-01 2025-03-31 12763585 bus:Director2 2025-03-31 12763585 bus:Director2 2023-08-01 2024-03-31 12763585 2023-08-01 12763585 bus:LeadAgentIfApplicable 2024-04-01 2025-03-31 12763585 2023-08-01 2024-03-31 12763585 2024-03-31 12763585 core:WithinOneYear 2024-03-31 12763585 core:AfterOneYear 2024-03-31 12763585 bus:EntityAccountantsOrAuditors 2023-08-01 2024-03-31 12763585 core:CostValuation core:Non-currentFinancialInstruments 2025-03-31 12763585 core:CostValuation core:Non-currentFinancialInstruments 2024-03-31 12763585 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2025-03-31 12763585 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2025-03-31 12763585 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-03-31 12763585 core:Non-currentFinancialInstruments 2025-03-31 12763585 core:Non-currentFinancialInstruments 2024-03-31 12763585 core:ShareCapital 2025-03-31 12763585 core:ShareCapital 2024-03-31 12763585 core:RetainedEarningsAccumulatedLosses 2025-03-31 12763585 core:RetainedEarningsAccumulatedLosses 2024-03-31 12763585 dpl:Item1 2024-04-01 12763585 dpl:Item1 2025-03-31 12763585 dpl:Item1 2023-08-01 12763585 dpl:Item1 2024-03-31 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 12763585
England and Wales

 

 

 

J & V PHARMA LIMITED



Abridged Accounts
 


Period of accounts

Start date: 01 April 2024

End date: 31 March 2025
Report to the directors on the preparation of the unaudited statutory accounts of J & V Pharma Limited for the year ended 31 March 2025

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of J & V Pharma Limited for the year ended 31 March 2025 which comprise of the Profit and Loss Account, the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity and the related notes from the companys accounting records and from information and explanations you have given us

As a practising member firm of the Association of Chartered Certified Accountants, we are subject to its ethical and other professional requirements which are detailed at
http://rulebook.accaglobal.com/

This report is made solely to the Board of Directors of J & V Pharma Limited, as a body, in accordance with the terms of our engagement letter dated 09 June 2024 Our work has been undertaken solely to prepare for your approval the accounts of J & V Pharma Limited and state those matters that we have agreed to state to the Board of Directors of J & V Pharma Limited, as a body, in this report in accordance with the requirements of the Association of Chartered Certified Accountants as detailed at http://www.accaglobal.com/factsheet163. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than J & V Pharma Limited and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that J & V Pharma Limited has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of J & V Pharma Limited. You consider that J & V Pharma Limited is exempt from the statutory audit requirement for the year

We have not been instructed to carry out an audit or a review of the accounts of J & V Pharma Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts
31 March 2025



....................................................
Bharat D Hathi Ltd
Portsmouth Technopole
Kingston Crescent
Portsmouth
Hampshire
PO2 8FA
14 June 2025
1
 
 
Notes
 
2025
£
  2024
£
Fixed assets      
Investments 3 843,528    843,528 
843,528    843,528 
Current assets      
Debtors 40,321    80,241 
Cash at bank and in hand 10,517    968 
50,838    81,209 
Creditors: amount falling due within one year (893,908)   (924,279)
Net current assets (843,070)   (843,070)
 
Total assets less current liabilities 458    458 
Net assets 458    458 
 

Capital and reserves
     
Called up share capital 1,000    1,000 
Profit and loss account (542)   (542)
Shareholders' funds 458    458 
 


For the year ended 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:
  1. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
  2. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the profit and loss account has not been delivered to the Registrar of Companies.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with section 444(2A).
The financial statements were approved by the board of directors on 14 June 2025 and were signed on its behalf by:


-------------------------------
Mr Jiten Hemraj Shingdia
Director
2
General Information
J & V Pharma Limited is a private company, limited by shares, registered in England and Wales, registration number 12763585, registration address 145 Sultan Road, Portsmouth, Hampshire, PO2 7AT.

The presentation currency is £ sterling.
1.

Accounting policies

Significant accounting policies
Statement of compliance
These financial statements have been prepared in compliance with FRS 102 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.
Basis of preparation
The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies.
The financial statements are prepared in sterling which is the functional currency of the company.
Turnover
Turnover comprises the fee charged to subsidiary companies.
Fixed asset investments
Fixed asset investments are stated at cost less provision for any permanent diminution in value.
2.

Average number of employees

Average number of employees during the year was 0 (2024 : 0).
3.

Investments

Cost Investments in group undertakings   Total
  £   £
At 01 April 2024 843,528    843,528 
Additions  
Transfer to/from tangible fixed assets  
Disposals  
At 31 March 2025 843,528    843,528 

3